Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Breast cancer, female
Stage/Subtype:  breast cancer in situ
Results 1-25 of 56 for your search:
Start Over
Safety and Efficacy Study of the Xoft® Axxent® eBx™ IORT System
Status: Active
Phase: Phase IV
Type: Treatment
Age: 40 and over
Trial IDs: CTPR-0009, NCI-2013-01601, NCT01644669
Metformin Hydrochloride in Preventing Breast Cancer in Patients with Atypical Hyperplasia or In Situ Breast Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 25 to 55
Trial IDs: A211102, NCI-2013-00995, CALGB-A211102, NCT01905046
Yoga or Stretching and Relaxation in Improving Physical Function in Patients with Stage 0-III Breast Cancer Undergoing Radiation Therapy
Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: 2009-0976, NCI-2012-01895, NCT01202851
Bioimpedance Spectroscopy in Quantification of Lymphedema in Patients with Breast Cancer
Status: Active
Phase: Phase III
Type: Diagnostic
Age: 18 and over
Trial IDs: 11-325, NCI-2012-00144, NCT01544335
Therapeutic Melatonin in Treating Cancer-Related Fatigue in Breast Cancer Patients Undergoing Radiation Therapy
Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: MCC-12-08248, NCI-2015-00345, NCI-2015-00317, NCT02332928
Proton Beam Radiation Therapy or Photon Beam Radiation Therapy in Treating Patients with Non-Metastatic Breast Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 21 and over
Trial IDs: UPCC 19115, NCI-2015-01950, 823440, RTOG 3509, RTOG 3510, UPC 19115, NCT02603341
Oxybutynin Chloride in Managing Hot Flashes
Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: ACCRU-SC-1603, NCI-2016-01603, NCT02961790
Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)
Status: Not yet active
Phase: Phase III
Type: Supportive care
Age: 49 and under
Trial IDs: 16-000817, NCI-2016-01396, NCT03025139
Accelerated Partial Breast Irradiation in Treating Patients with Low-Risk Stage 0-I Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 50 and over
Trial IDs: 201401160, NCI-2014-00269, NCT02076074
VST-1001 (Dilute Fluorescein) for Lymphatic Mapping & Localization of Lymph Nodes in Patients With Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: VST-1001-02, NCI-2014-02431, 2013-1021, NCT02294565
Accelerated Whole Breast Radiotherapy in Treating Patients with Breast Cancer Who Have Undergone Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 040807, NCI-2012-00535, CDR0000643276, CINJ-040807, NCT00909909
High Dose Rate Brachytherapy in Treating Patients with Endometrial, Cervical, Lung, Breast, or Prostate Cancer
Status: Active
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 18 to 90
Trial IDs: 09-C-0100, NCI-2013-01448, 090100, 302844, P08407, NCT00924027
Laboratory Treated T Cells after Chemotherapy in Treating Patients with HER2-Negative Stage II-III Breast Cancer That Can Be Removed by Surgery
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2010-056, NCI-2011-02634, 1005008403, CDR0000675211, NCT01658969, WSU-2010-056, NCT01147016
Radiation Therapy in Treating Patients with Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2009-0818, NCI-2011-01102, NCT01245712
Breast-Conserving Surgery and Radiation Therapy in Treating Patients with Multiple Ipsilateral Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 40 and over
Trial IDs: Z11102, NCI-2012-00707, ACOSOG-Z11102, CDR0000728605, NCT01556243
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201301106, NCI-2012-02202, NCT01723774
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 50 and over
Trial IDs: BRE007-12, NCI-2016-00072, NCT01766297
Omega-3 Fatty Acid in Treating Patients with Stage I-III Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CCCWFU 98113, NCI-2013-00963, NCT01869764
Naltrexone Hydrochloride in Reducing Radiation Therapy Related Fatigue in Patients with Breast Cancer
Status: Temporarily closed
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 14-056, NCI-2014-02031, NCT02137252
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: NCI2013-01-03, NCI-2014-02412, HHSN2612201200035I, N01-CN-2012-00035, NWU2013-01-03, NCT02314156
Hypofractionated Regional Nodal Radiation Therapy in Treating Older Patients with Breast Cancer Who Have Undergone Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and over
Trial IDs: MCC-15-10994, NCI-2015-01317, NCT02515110
Boost Radiation Therapy before Surgery in Treating Patients with Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: Pro00063936, NCI-2015-01625, NCT02482389
Single-Fraction Partial Breast Radiation Therapy before Surgery in Treating Patients with Early Stage Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: Pro00063848, NCI-2015-01856, NCT02482376
Nelipepimut-S plus GM-CSF Vaccine Therapy in Treating Patients with Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2016-0164, NCI-2015-02189, N01-CN-2012-00034, MDA2014-04-02, NCT02636582
A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ATOS-2015-007, NCI-2016-00299, NCT02540330
Start Over